295 related articles for article (PubMed ID: 21382134)
21. [Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].
Siegmund B; Pollmann H; Richter H; Orlovic M; Gottstein S; Klamroth R
Hamostaseologie; 2010 Nov; 30 Suppl 1():S37-9. PubMed ID: 21042673
[TBL] [Abstract][Full Text] [Related]
22. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
23. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
[TBL] [Abstract][Full Text] [Related]
25. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
Zhang L; Zhao Y; Sun J; Wang X; Yu M; Yang R
Haemophilia; 2011 Mar; 17(2):191-5. PubMed ID: 20860578
[TBL] [Abstract][Full Text] [Related]
26. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.
Aznar JA; Moret A; Ibáñez F; Vila C; Cabrera N; Mesa E; Bonanad S
Haemophilia; 2014 Sep; 20(5):624-9. PubMed ID: 24697977
[TBL] [Abstract][Full Text] [Related]
28. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
[TBL] [Abstract][Full Text] [Related]
29. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
30. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
Nemes L; Pollmann H; Becker T
Haemophilia; 2012 Jul; 18(4):496-502. PubMed ID: 22250808
[TBL] [Abstract][Full Text] [Related]
31. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
Valentino LA; Negrier C; Kohla G; Tiede A; Liesner R; Hart D; Knaub S
Haemophilia; 2014 Jan; 20 Suppl 1():1-9. PubMed ID: 24330348
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
[TBL] [Abstract][Full Text] [Related]
33. Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
Holstein K; Marx G; Lentz B; Bokemeyer C; Langer F
Hamostaseologie; 2012; 32 Suppl 1():S48-51. PubMed ID: 22960877
[TBL] [Abstract][Full Text] [Related]
34. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients.
Schep SJ; Fischer K; Boes M; Schutgens REG
Haemophilia; 2023 Jul; 29(4):1039-1048. PubMed ID: 37276354
[TBL] [Abstract][Full Text] [Related]
35. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
[TBL] [Abstract][Full Text] [Related]
36. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
Franchini M; Lippi G
Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
[TBL] [Abstract][Full Text] [Related]
37. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
[TBL] [Abstract][Full Text] [Related]
38. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
Marcucci M; Mancuso ME; Santagostino E; Kenet G; Elalfy M; Holzhauer S; Bidlingmaier C; Escuriola Ettingshausen C; Iorio A; Nowak-Göttl U
Thromb Haemost; 2015 May; 113(5):958-67. PubMed ID: 25631402
[TBL] [Abstract][Full Text] [Related]
39. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.
Ivaskevicius V; Goldmann G; Horneff S; Marquardt N; Klein C; Albert T; Zeitler H; Oldenburg J
Hamostaseologie; 2014; 34 Suppl 1():S9-12. PubMed ID: 25382774
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
Elm T; Karpf DM; Øvlisen K; Pelzer H; Ezban M; Kjalke M; Tranholm M
Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
